Art raffles generate substantial funding for Alzheimer’s research and support programs by leveraging high-value artworks to attract global participation. The ongoing “1 Picasso for 100 Euros” campaign, now in its third edition, exemplifies this approach: by offering an original 1941 Pablo Picasso painting titled “Tête de Femme” valued at €1 million to raffle participants, the campaign has already sold approximately 60,000 of 120,000 available €100 tickets as of March 2026, with projections suggesting €12 million in total fundraising for Alzheimer’s research if all tickets sell. These funds directly support the Fondation Recherche Alzheimer, a French organization dedicated to advancing scientific understanding of the disease and improving quality of life for patients and families. This article explores how art raffles work as a fundraising mechanism, the specific impact of the current Picasso campaign, and what this model reveals about innovative approaches to supporting brain health research.
Table of Contents
- How Does an International Art Raffle Support Alzheimer’s Research?
- The Painting at the Center of the Campaign and Its Global Appeal
- How the Funds Support Research and Patient Support Programs
- Participating in an Art Raffle: Ticket Pricing, Accessibility, and What to Expect
- The Reality of Art Raffle Fundraising: Limitations and Long-Term Viability
- The Global Expansion of Picasso Raffles for Medical Research
- What Art Raffles Reveal About the Future of Medical Research Funding
- Conclusion
How Does an International Art Raffle Support Alzheimer’s Research?
Art raffles function as a direct-to-consumer fundraising mechanism that bypasses traditional grant structures and corporate donations. Rather than relying on institutional fundraising or government funding—which often involves lengthy application processes and restricted budgets—an art raffle sells tickets to the general public at a fixed price, with the prize being a valuable artwork. The “1 Picasso for 100 Euros” campaign opened November 24, 2025, and will conduct its drawing on April 14, 2026, at Christie’s Paris, livestreamed globally. Each €100 ticket represents a voluntary contribution to Alzheimer’s research, with the understanding that one winner receives the painting while the organization retains all ticket revenue.
The financial model is straightforward: 120,000 tickets multiplied by €100 per ticket equals €12 million in gross revenue. After accounting for the cost of acquiring the Picasso painting and administrative expenses, the majority flows directly to the Fondation Recherche Alzheimer for research and support programs. This structure means that unlike traditional charity galas or pledge drives, participants have a tangible incentive—the possibility of owning a museum-quality artwork—while researchers gain predictable, substantial funding. The model also has global reach; participants from multiple countries can purchase tickets, making the campaign accessible beyond France’s borders and broadening the donor base beyond wealthy art collectors to anyone interested in supporting Alzheimer’s research.
The Painting at the Center of the Campaign and Its Global Appeal
The prize, Pablo Picasso’s “Tête de Femme” (Head of a Woman) from 1941, is a work of significant historical and artistic importance. Created during World War II, the painting exemplifies Picasso’s cubist approach and carries both aesthetic and historical weight that elevates it beyond a simple prize—it becomes a symbol of the campaign itself. This is deliberate: high-value artworks attract media attention and cultural prestige that generic fundraising cannot achieve. The painting’s €1 million valuation is not arbitrary; it reflects assessed market value and creates credibility with potential raffle participants who want assurance they might win something genuinely valuable.
However, there is an important limitation to this fundraising approach: it only works for campaigns that can acquire genuinely significant artworks, which requires either wealthy donor support or institutional partnerships. The “1 Picasso for 100 Euros” campaign operates through Christie’s, one of the world’s largest auction houses, which provides expertise and credibility but also limits replicability. Smaller Alzheimer’s organizations without access to major artworks or auction house partnerships cannot easily use this model. Additionally, the appeal of an original Picasso reflects a level of cultural capital and wealth concentration that raises questions about equity in fundraising—not all communities have equal interest in or access to participate in art raffles, potentially skewing participation toward higher-income demographics in developed countries.
How the Funds Support Research and Patient Support Programs
Approximately €6 million (after expenses) from a fully subscribed campaign would support multiple research priorities identified by the Fondation Recherche Alzheimer. These funds typically go toward grants for innovative research projects aimed at understanding disease mechanisms, developing new diagnostic tools, and creating therapeutic interventions. Support programs funded through these campaigns include patient and caregiver support services—counseling, educational programs, respite care resources, and community initiatives that help families navigate the emotional and practical challenges of an Alzheimer’s diagnosis.
The distinction between research funding and support programs is critical: while new drug development and biomarker research capture headlines, the lived reality of Alzheimer’s patients and families depends equally on accessible support services. A family struggling with behavioral changes in a recently diagnosed loved one needs practical guidance and emotional support immediately, not necessarily a breakthrough drug that may arrive in a decade. The “1 Picasso for 100 Euros” campaign’s stated goal is to fund both categories—”innovative scientific programs aimed at better understanding disease mechanisms, developing new treatments, and improving quality of life”—which acknowledges this dual need. However, the organization’s actual allocation between research and support spending is not specified in publicly available information, meaning participants have limited visibility into exactly how their €100 contribution will be divided.
Participating in an Art Raffle: Ticket Pricing, Accessibility, and What to Expect
Each ticket costs €100 (approximately $115–$117 USD), placing participation within reach of middle-income individuals while remaining meaningful enough to feel like a genuine contribution. The ticket price is deliberately accessible—not so cheap that it trivializes the campaign, but not so expensive that it restricts participation to wealthy individuals. This represents a practical advantage over traditional charity auctions, where minimum bids may start at thousands of dollars. A person could purchase one ticket as a modest donation to Alzheimer’s research while maintaining the small possibility of an extraordinary outcome. For U.S.
participants, purchasing a ticket involves currency conversion and navigating international regulations around raffles and gambling, which vary by state. While the official campaign organizers handle the logistics, some U.S. jurisdictions have restrictions on participating in raffles sponsored by foreign organizations, making legal participation dependent on individual state law. The draw will occur April 14, 2026, meaning participants commit to waiting approximately five months from the sale opening date for results. A significant consideration: while a €1 million painting is objectively valuable, the actual value to a winner depends on their ability to sell it, insure it, display it, or authenticate it through proper channels. Winning a Picasso does not automatically translate to €1 million in liquid assets—that requires navigating the art market and potentially paying capital gains taxes, which could substantially reduce the net financial benefit.
The Reality of Art Raffle Fundraising: Limitations and Long-Term Viability
Art raffles generate impressive amounts in a single campaign but present sustainability challenges for ongoing Alzheimer’s research funding. The “1 Picasso for 100 Euros” format has been executed three times globally, suggesting that this specific model has a replicable, if not infinitely sustainable, structure. However, each edition requires acquiring a valuable artwork, maintaining auction house partnerships, generating media attention, and managing complex international logistics. The model works when art and research alignment captures public imagination—a Picasso and Alzheimer’s research form a compelling narrative—but cannot easily scale into a permanent fundraising infrastructure. Another limitation is that the campaign’s success depends on scarcity and novelty.
The first edition of “1 Picasso for 100 Euros” generated significant global attention partly because it was unprecedented. By the third edition (the current one), media coverage has declined and novelty has diminished, which may explain why only 50 percent of available tickets had sold as of March 2026. This suggests a ceiling on the model’s effectiveness. For sustainable Alzheimer’s funding, art raffles work best as periodic, high-impact campaigns complementing ongoing institutional fundraising, grants, and government support—not as a primary funding source. Organizations depending entirely on art raffle revenue would face unpredictable annual budgets and unable to commit to long-term research commitments, which require multi-year funding security.
The Global Expansion of Picasso Raffles for Medical Research
The current campaign represents the third iteration of the “1 Picasso for 100 Euros” model, indicating that previous editions were successful enough to justify repeating the approach. The campaign’s international scope—accessible to participants worldwide, conducted through Christie’s, and marketed globally—demonstrates growing recognition that art and medical research fundraising can merge effectively. The 120,000-ticket cap creates artificial scarcity, which is a marketing strategy that increases perceived value and urgency for potential purchasers.
What makes this third edition noteworthy is its timing during ongoing inflation and economic uncertainty in developed economies. Despite these broader economic conditions, the campaign has attracted sufficient participation to move 60,000 tickets (50 percent of inventory) in approximately four months. This suggests sustained global interest in combining art ownership with charitable contribution, even when discretionary spending is constrained. The draw date of April 14, 2026, falls within the campaign period being described, meaning interested readers may still have opportunity to participate if tickets remain available.
What Art Raffles Reveal About the Future of Medical Research Funding
The success of art-based fundraising challenges conventional assumptions about how medical research gets funded. Historically, Alzheimer’s research has relied on pharmaceutical company investments, government grants (NIH, Horizon Europe), and traditional nonprofit fundraising. The emergence of creative mechanisms like art raffles suggests that the most significant barrier to funding is not lack of money but lack of compelling narratives that connect donors to causes. A person might be unmotivated by a standard Alzheimer’s Association fundraiser but engaged by the possibility of owning a Picasso while supporting research.
This model also suggests a potential future where cultural institutions—museums, auction houses, galleries—become more directly aligned with medical research funding. Rather than treating art and science as separate sectors, integrated campaigns recognize that high-net-worth art collectors and general publics interested in both art and health outcomes represent an untapped fundraising base. As Alzheimer’s research increasingly requires billions in funding to produce meaningful breakthroughs, diversified fundraising approaches become essential. However, this reliance on novelty and cultural prestige also means that underrepresented health conditions—those lacking compelling artistic or celebrity advocates—may continue to struggle for funding despite equal scientific merit.
Conclusion
Art raffles like the “1 Picasso for 100 Euros” campaign demonstrate that innovative fundraising mechanisms can direct substantial resources toward Alzheimer’s research while engaging global audiences. The current campaign has already generated significant funding for the Fondation Recherche Alzheimer, with projections of €12 million if all tickets sell, supporting both research into disease mechanisms and support programs for patients and families. While art raffles offer unique advantages—accessible ticket pricing, global reach, and cultural prestige—they also carry limitations as sustainable funding sources, require valuable artworks and institutional partnerships, and work best as periodic campaigns rather than permanent infrastructure.
For individuals interested in supporting Alzheimer’s research, participation in the ongoing “1 Picasso for 100 Euros” raffle represents a way to contribute directly while maintaining a (small) possibility of acquiring a significant artwork. The campaign’s third edition continues through April 14, 2026, when the drawing occurs at Christie’s Paris. Whether this model expands further or remains a periodic campaign, it reveals that the most effective medical research funding often combines genuine cause alignment with human incentives—the possibility that support for research might, improbably, result in something extraordinary.
You Might Also Like
- Harvard Researchers Optimistic About New Era in Alzheimer’s Care
- Caregiver Education Conference Launches in Partnership With Alzheimer’s Groups
- Brain Stimulation Collaboratory Develops New Alzheimer’s Care Models
For more, see Alzheimer’s Association — medical tests.
